First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.03.05.21252590: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Written informed consent was obtained from recruited patients. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Evaluation of SARS-CoV-2-spike-specific IgM, IgA, IgG: For B cells evaluation, 2 million PBMNCs were stained for 30 minutes at 4°C with fluorochrome-conjugated antibodies listed in Table S4, then washed with PBS/EDTA buffer (PEB), and incubated 5 minutes with 7-AAD for viability evaluation. IgA , IgGsuggested: NoneSoftware and Algorithms Sentences Resources Evaluation of SARS-CoV-2-spike-reactive T cells: For T cells stimulation in … SciScore for 10.1101/2021.03.05.21252590: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Written informed consent was obtained from recruited patients. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Evaluation of SARS-CoV-2-spike-specific IgM, IgA, IgG: For B cells evaluation, 2 million PBMNCs were stained for 30 minutes at 4°C with fluorochrome-conjugated antibodies listed in Table S4, then washed with PBS/EDTA buffer (PEB), and incubated 5 minutes with 7-AAD for viability evaluation. IgA , IgGsuggested: NoneSoftware and Algorithms Sentences Resources Evaluation of SARS-CoV-2-spike-reactive T cells: For T cells stimulation in vitro, 1.5 million PBMNCs were cultured in complete RPMI plus 5% human AB serum in 96 well flat bottom plates in presence of medium alone (background, negative control) or of a pool of spike SARS-CoV-2 peptide pools (Prot_S1, Prot_S+ and Prot_S to achieve a complete sequence coverage of the spike protein) at 0.6 µM/peptide, accordingly to manufacturer’s instructions (Miltenyi Biotech). Prot_Ssuggested: NoneEvaluation of SARS-CoV-2-specific IgM and IgG: Evaluation of SARS-CoV-2-spike specific IgG (Diasorin) and IgM (Abbott), Nucleoprotein-specific IgG (Abbott), RBD-specific IgG (Abbott), S-neutralizing Ig (Dia.Pro Diagnostic Bioprobes) were performed following manufacturer’s instructions. Abbottsuggested: (Abbott, RRID:SCR_010477)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
